# P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Source: https://onco.cc/trials/nct06468033/  
OnCo record `nct06468033` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.

## Summary

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk is a phase 3 interventional study registered as NCT06468033 by PharmaEssentia, with 160 participants enrolled, started 2025-07-18 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ropeginterferon alfa-2b, Placebo. Conditions listed: Primary Myelofibrosis, Myeloproliferative Neoplasm. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06468033
- Phase: 3
- Setting: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study
- Sponsor: PharmaEssentia
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06468033: https://clinicaltrials.gov/study/NCT06468033

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)
- companies: [PharmaEssentia](https://onco.cc/companies/pharmaessentia/)

---
JSON: https://onco.cc/api/v1/entities/nct06468033.json